Structure Therapeutics has seen a sharp reset in market sentiment this year, which puts fresh focus on whether the current ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

In March 2025 I doubled down on my Buy rating for the stock of Structure Therapeutics (GPCR), despite stock having sunk in value by ~40% since my first Buy call, issued in August 2024. Today, stock is ...

In a post-Metsera world, Structure TherapeuticsGPCR could be the next big takeover candidate, analysts said Tuesday, as Big Pharma scrambles to play catch-up in the blazing hot obesity space. The ...

The market for drugs that mimic glucagon-like peptide 1 or GLP-1 is hard to overstate. Tirzepatide, which Eli Lilly markets as Mounjaro for patients with diabetes, and Zepbound for patients seeking ...

The stock of Structure Therapeutics rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug. The stock rose 8% to $58.07 in premarket trading ...

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

The somewhat alarmist commercial -- "obesity is America's deadliest epidemic," intoned the narrator -- touted one of the higher-potential Hims & Hers' offerings, its compounded semaglutide weight loss ...

Structure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP-1 drug aleniglipron. The weight-loss treatment was put through its paces ...